Application of physiologically‐based pharmacokinetic model approach to predict pharmacokinetics and drug–drug interaction of rivaroxaban: A case study of rivaroxaban and carbamazepine

Application of physiologically‐based pharmacokinetic model approach to predict pharmacokinetics and drug–drug interaction of rivaroxaban: A case study of rivaroxaban and carbamazepine

Abstract Rivaroxaban (RIV; Xarelto; Janssen Pharmaceuticals, Beerse, Belgium) is one of the direct oral anticoagulants. The drug is a strong substrate of cytochrome P450 (CYP) enzymes and efflux transporters. This study aimed to develop a physiologically‐based pharmacokinetic (PBPK) model for RIV. I...

Full description

Bibliographic Details
Main Authors: Lien Thi Ngo, Sung‐yoon Yang, Sooyoung Shin, Duc Tuan Cao, Hung Van Nguyen, Sangkeun Jung, Jae‐Young Lee, Jong‐Hwa Lee, Hwi‐yeol Yun, Jung‐woo Chae
Format: Article
Language:English
Published: Wiley 2022-11-01
Series:CPT: Pharmacometrics & Systems Pharmacology
Online Access:https://doi.org/10.1002/psp4.12844

Internet

https://doi.org/10.1002/psp4.12844

Similar Items